Amgen is set to present comprehensive data from its Phase 2 MariTide study alongside new findings from its Repatha® and VESALIUS-REAL studies at the upcoming 85th American Diabetes Association Scientific Sessions in Chicago. The presentations aim to highlight significant advancements in obesity and Type 2 diabetes treatments.
Phase 2 MariTide Study Highlights
MariTide, Amgen’s investigational long-acting peptide-antibody conjugate, demonstrated robust weight loss outcomes over a 52-week period without a plateau in patients with obesity, both with and without Type 2 diabetes. These results, initially announced in November 2024, provide crucial insights into the drug’s efficacy and safety, shaping the design of the subsequent Phase 3 MARITIME program.
Additional Cardiometabolic Research
In addition to MariTide, Amgen will present data from the Phase 3 FOURIER study of Repatha®, which explores its benefits in cardiovascular disease, and the VESALIUS-REAL study focusing on real-world lipid management patterns. These presentations underscore Amgen’s commitment to addressing critical health challenges through innovative therapies.
- MariTide’s dual mechanism of action may offer enhanced durability in weight management.
- Repatha® continues to show potential in reducing cardiovascular risks in diverse patient populations.
- Real-world data from VESALIUS-REAL could inform future lipid management strategies.
The symposium on June 23 will delve into 52-week efficacy data, safety profiles, and insights from the pharmacokinetics low dose initiation study. Concurrently, Amgen plans to engage with the investment community through a webcast, providing a platform for detailed discussions on the MariTide program.
At the ADA Scientific Sessions, attendees can also participate in interactive experiences, including a word cloud project and immersive video content, further emphasizing Amgen’s dedication to advancing medical knowledge and patient care.
The presentation of these studies not only highlights significant progress in treating obesity and cardiovascular diseases but also reflects Amgen’s strategic focus on developing therapies that address multifaceted health conditions. By leveraging innovative approaches and extensive research, Amgen continues to position itself at the forefront of biotechnological advancements.
Amgen’s proactive engagement with the scientific community and investors ensures that the potential of its drug candidates is thoroughly communicated and understood, paving the way for future developments and collaborations in the healthcare sector.
The advancement of MariTide and Repatha® exemplifies Amgen’s dedication to creating impactful treatments that can significantly improve patient outcomes and address some of the most pressing health issues globally.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
